Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $83.1 million.

  • Autolus Therapeutics' Total Current Liabilities rose 5830.89% to $83.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.1 million, marking a year-over-year increase of 5830.89%. This contributed to the annual value of $60.7 million for FY2024, which is 3577.8% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Total Current Liabilities of $83.1 million as of Q3 2025, which was up 5830.89% from $68.2 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Total Current Liabilities peaked at $83.1 million during Q3 2025, and registered a low of $28.2 million during Q2 2021.
  • Over the past 5 years, Autolus Therapeutics' median Total Current Liabilities value was $40.9 million (recorded in 2024), while the average stood at $44.8 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Total Current Liabilities tumbled by 1511.27% in 2021, and later soared by 6661.21% in 2025.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Total Current Liabilities stood at $28.6 million in 2021, then skyrocketed by 62.4% to $46.4 million in 2022, then fell by 3.51% to $44.7 million in 2023, then skyrocketed by 35.78% to $60.7 million in 2024, then surged by 36.76% to $83.1 million in 2025.
  • Its last three reported values are $83.1 million in Q3 2025, $68.2 million for Q2 2025, and $66.6 million during Q1 2025.